` ATH (Alterity Therapeutics Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

ATH
vs
S
S&P/ASX 300

Over the past 12 months, ATH has significantly outperformed S&P/ASX 300, delivering a return of +33% compared to the S&P/ASX 300's +7% growth.

Stocks Performance
ATH vs S&P/ASX 300

Loading
ATH
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ATH vs S&P/ASX 300

Loading
ATH
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
ATH vs S&P/ASX 300

Loading
ATH
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Alterity Therapeutics Ltd vs Peers

S&P/ASX 300
ATH
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Alterity Therapeutics Ltd
Glance View

Market Cap
87m AUD
Industry
Biotechnology

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. The company is headquartered in Melbourne, Victoria and currently employs 11 full-time employees. The company went IPO on 2000-03-28. The firm focuses on developing disease modifying treatments for neurodegenerative conditions. The firm's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The firm also has a drug discovery platform generating chemical to intercede in disease processes.

ATH Intrinsic Value
0.045 AUD
Undervaluation 82%
Intrinsic Value
Price
Back to Top